New Board members will provide expert insight into ADME-Tox, biomarker, assay, cell and gene therapy, and immuno-oncology advances
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its new Scientific Advisory Board (SAB) comprised of experts in ADME-Tox, drug development, cell and gene therapy, immuno-oncology, and clinical diagnostics.
“I am proud to introduce BioIVT’s highly distinguished new SAB members. Our Board members were carefully chosen and are all eminent in their field. They have the skills…
• Stevenage Bioscience Catalyst celebrates its 10th anniversary
• Events focus on the cutting-edge science of our occupier companies
• The campus is now at the heart of the biggest cluster for cell and gene therapy in Europe.
STEVENAGE 11th July 2022: Stevenage Bioscience Catalyst (SBC) is celebrating 10 years since it opened its doors to life sciences companies. A series of events was held on 6th July to celebrate the some of the breakthrough science being undertaken on campus including a science symposium, celebration lunch and scientific poster exhibition.
Dr Sally Ann Forsyth OBE, CEO of…
Innovate UK is offering small and micro businesses a share of up to £30 million in grants alongside tailored business support delivered by Innovate UK EDGE. You can apply for up to £50,000 for highly innovative ideas that have a clear route to commercialisation through business growth.
Your project must lead to new products, processes or services that are significantly ahead of others currently available, or propose an innovative use of existing products, processes or services. It can also involve a new or innovative business model.
In your application, you must be able to show…
RevoluGen Wins 2022 BioNewsRound Award for Translational Research
First Automated Benchtop Fire Monkey HMW-DNA Extraction Installed at Quadram Institute for Pathogen Sequencing and AMR Monitoring
London, UK – 08 July 2022 – UK genomics company, RevoluGen Ltd. (RevoluGen or the Company), is pleased to announce that it has been selected as the winner of the 2022 BioNewsRound Award, for the development and automation of its Fire Monkey High Molecular Weight (HMW) DNA extraction system and successful transfer to its collaborator, Quadram Institute Biosciences (Quadram).
The Award, organised by…
Are you in need a drug delivery system to bring your candidate molecules inside the cell? Are you tired of long and tedious collaborations? Can you imagine being able to arrive at the clinic with your candidate molecule? DIVERSA helps you with your drug delivery challenges.
DIVERSA is a spin-off of the Health Research Institute of Santiago de Compostela (IDIS) and the Servizo Galego de Saúde (SERGAS) established in January 2022. DIVERSA is the exclusive licensee of a new drug delivery technology based on lipid nanoemulsions for small drugs and macromolecules (peptides, proteins, and…
• Further plans for Stevenage campus expansion shared
• Developer partners announced as Reef Group and UBS Asset Management
• GSK to gift land to SBC to enable expansion
STEVENAGE 4th July: Stevenage Bioscience Catalyst (SBC) is based on the life science campus in Stevenage, Hertfordshire. Details of plans to expand the campus were shared today.
The new campus, which will be one of the largest of its kind in the UK and Europe, will be built alongside SBC and its 40+ occupier companies, the Cell and Gene Therapy Catapult and GSK’s existing Global R&D centre. UBS Asset Management and Reef…
05 July 2022
Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Utilizing Mogrify’s proprietary direct cellular reprogramming platform, the…
Cambridge, UK, 4 July 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation as part of the Short Oral Discussion Session A at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting, which will be held from 19-23 September 2022 in Stockholm, Sweden and online.
The presentation will take place on Tuesday 20…
Jun 28, 2022
Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates
SAN DIEGO, June 28, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina Accelerator, located in both San Francisco and…